Search results
35 Years After Tiananmen, China’s Conduct Again Triggers Alarm
The Wall Street Journal· 4 days agoXi’s governing philosophy today reflects the twin crises of 1989, according to China scholar Joseph...
NIO is building its third EV plant as it can no longer meet demand
Electrek· 1 day agoWho said EV sales were slowing? NIO kicked off construction on its third EV plant as the existing...
China Market Update: Meituan Beats As Real Estate Retreats
Forbes· 12 hours agoAsian equities were largely higher overnight, while Mainland China underperformed.
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoSHANGHAI, China, May 31, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider,
Yum China's Popular Children's Day Promotions Highlight its Innovative Approach to IP Collaboration
The Pilot News· 3 days agoYum China Holdings, Inc. (the "Company" or "Yum China", NYSE: YUMC and HKEX: 9987) today announced that in celebration of Children's ...
NIO Stock: Nio Gets Go-Ahead for Third EV Factory in China. What to Know.
InvestorPlace· 1 day agoThis site would be Nio’s third EV production facility in China and significantly boost the company’s...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored...
Morningstar· 2 days agoCAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta
Xiao-I Expands Business into the B2C Market with Three Product Launches
Digital Journal· 3 days agoThe newest, fastest-growing and most disruptive newswire available today.
Firan Technology Group Corporation (“FTG”) Awarded $17M CAD Contract to Supply Cockpit Interface...
Digital Journal· 20 hours agoThe Corporation’s shares are traded on the Toronto Stock Exchange under the symbol FTG. FORWARD-LOOKING STATEMENTS This news release contains certain forward-looking statements ...
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are...
Yucaipa News Mirror· 5 days ago...high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor (TKI),...